Digital Transformation in Pharma CRM: Enhancing HCP Engagement
Digital channels are increasingly preferred by HCPs over traditional in-person interactions.
High impact 30 min
Updated daily from FDA, EMA, ICH and leading publishers
The pharma industry's research library
Curated regulatory guidance, clinical analyses, and market reports. AI-summarized, editor-reviewed, instantly downloadable.
39whitepapers
8publishers
6regions
Dailyupdates
Research Pulse
Aggregated from live regulatory feeds 39 Research reports In library
8 Publishers FDA, EMA, industry
3 Featured Editor picks
6 Gated downloads Lead-gen reports
Quick answer
NovaPharmaNews hosts 39 curated pharmaceutical whitepapers and industry reports from 8 publishers — FDA and EMA regulatory guidance, clinical analyses, manufacturing intelligence, and market research. 3 featured reports are editor-picked this week. Each landing page includes key takeaways, optional PDF download, and links to related drugs, companies, and pipeline data.
Methodology & data sources Publications & analysis Editorial policy
Browse the library
39 results 
RYBREVANT® Access and Reimbursement Guide Overview
RYBREVANT® is indicated for specific NSCLC mutations, including EGFR exon 19 deletions, exon 21 L858R substitution mutations, and exon 20 in…
High impact 84 min
Guidance on Developing Treatments for Stimulant Use Disorders
FDA has not yet approved any medications for stimulant use disorders.
Critical impact 28 min
Comparative Analysis of FDA and EMA Drug Approval Processes
The FDA employs a centralized and flexible approval system with expedited pathways, potentially leading to shorter review timelines.
High impact 28 min
GxP Environmental Monitoring Systems: A Guide for Small Biotechs
Essential guide for small biotechs on GxP environmental monitoring systems to ensure compliance and product quality.
High impact 36 min
FDA's April 30, 2026 ODAC Meeting on Camizestrant Review
Camizestrant is under review for the treatment of ESR1m/HR+/HER2- advanced breast cancer (ABC).
High impact 198 min
Data First: Enhancing Drug Development with FAIR-by-Design Standards
FAIR-by-design standardization is a necessary investment for maximizing NAM data utility.
High impact 28 min
Did You Know: Insights from NCPDP's Active Task Groups
NCPDP has 71 active task groups focusing on diverse areas of pharmacy standards.
High impact 74 min
A26 Informational Reports: Insights for Pharma Stakeholders
Total grants and donations received by the AMA in 2025 amounted to $3,666,000, supporting various public health initiatives.
High impact 300 min
🔒 Cigna Medical Coverage Policy: Acupuncture
Cigna covers acupuncture for tension-type headaches, migraine with or without aura, and musculoskeletal joint pain causing functional defici…
High impact 20 min
🔒 Medicare Risk Arrangement and Use and Outcomes Among Physician Groups
A JAMA Network Open study analyzed 5,278,717 person-years from 2016-2019 across 17 physician groups and 35 health insurers, finding at-risk …
High impact 20 min
🔒 Patient Mastering as Enterprise Infrastructure
Kythera Labs , founded in 2019, has raised $29.2 million to develop its Wayfinder Platform for healthcare data integration and patient maste…
High impact 8 min
🔒 Radiation Therapy: Fractionation, Image-Guidance, and Special Services (Idaho Only)
UnitedHealthcare's Idaho policy caps palliative bone metastases treatment at 10 fractions, aligning with ASTRO evidence-based guidelines tha…
High impact 11 min
🔒 Lilly's Weight-Loss Pill Approved, Sparking Competition with Novo Nordisk
The FDA approved Foundayo (orforglipron) tablets under NDA 220934 for adults with obesity or overweight with weight-related comorbidities, b…
High impact 15 min
Clinical Appropriateness Guidelines for Imaging of the Chest
The revised guidelines took effect April 4, 2026, following physician panel review on July 17, 2025. Changes include updates to pneumonia, l…
High impact 5 min
Drug Testing for Substance Use and Pain Management
Immunoassay screening at the point of care provides rapid results but requires LC-MS/MS confirmation for definitive identification of specif…
High impact 5 min
FDA Draft Guidance on AI in Drug Development Explained
The FDA released draft guidance "Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making" on January 6, …
High impact 5 min
🔒 ASHP Policy Positions 1982-2026
A comprehensive catalog of professional policy positions by ASHP, advocating for pharmacy practice and public health.
High impact 20 min
Frequently asked questions
What whitepapers does NovaPharmaNews publish?
Our research library curates FDA, EMA, and industry publisher PDFs — regulatory guidance, clinical analyses, manufacturing reports, and market intelligence. Each report includes an AI-summarized landing page with key takeaways and a gated PDF download.
How do I download a whitepaper?
Open any report page, scroll to the download form, and enter your work email. You receive instant PDF access and can opt in to weekly pharma intelligence updates. Downloads are free for healthcare professionals.
How do whitepapers connect to news and pipeline data?
Report pages link to related intelligence — company profiles, drug INN pages, clinical trials, pipeline programs, and topic hubs. Use the intelligence spokes on each page to explore the entity graph behind the research.
How often is the library updated?
New reports are ingested daily from leading publishers and regulatory sources. Featured picks highlight high-impact FDA, EMA, and industry research each week.